Form 6K NLS Pharmaceutics AG For: 17 July
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
NLS Pharmaceutics AG (NLSP)
NLS Pharmaceutics AG stock price live, this page displays NASDAQ NLSP stock exchange data. View the NLSP premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the NLS Pharmaceutics AG real time stock price chart below.
What Is the NLS Pharmaceutics AG Stock Price Today?
The NLS Pharmaceutics AG stock price today is 2.140.
What Is the Stock Symbol for NLS Pharmaceutics AG?
The stock symbol for NLS Pharmaceutics AG is ""NLSP.""
What Stock Exchange Does NLS Pharmaceutics AG Trade On?
NLS Pharmaceutics AG is listed and trades on the NASDAQ stock exchange.
Is NLS Pharmaceutics AG a Good Stock to Buy?
Determining whether NLS Pharmaceutics AG—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NLSP quote. (ISIN: CH1384053976)
What Is the NLS Pharmaceutics AG Stock Price Today?
The NLS Pharmaceutics AG stock price today is 2.140.
What Is the Stock Symbol for NLS Pharmaceutics AG?
The stock symbol for NLS Pharmaceutics AG is ""NLSP.""
What Stock Exchange Does NLS Pharmaceutics AG Trade On?
NLS Pharmaceutics AG is listed and trades on the NASDAQ stock exchange.
Is NLS Pharmaceutics AG a Good Stock to Buy?
Determining whether NLS Pharmaceutics AG—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NLSP quote. (ISIN: CH1384053976)
NASDAQ
Currency in USD
2.140
+0.120(+5.94%)
Closed·
After Hours
2.110-0.030(-1.40%)
·
Fair Value
An estimate of a NLS Pharmaceutics AG's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.990
2.180
52 wk Range
1.300
7.960
NLSP Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
NLSP is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a NLS Pharmaceutics AG's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.9902.180
52 wk Range
1.3007.960
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NLSP Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a NLS Pharmaceutics AG's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Form 6K NLS Pharmaceutics AG For: 30 June
- Investing.com
- Form 6K NLS Pharmaceutics AG For: 17 July
- Investing.com
- Form 6K NLS Pharmaceutics AG For: 30 June
- Investing.com
- Form 6K NLS Pharmaceutics AG For: 16 June
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
NLS Pharmaceutics AG Company Profile
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience for the treatment of narcolepsy; and Nolazol for the treatment of ADHD. The company also develops NLS-4, a selective dopamine reuptake inhibitor treatment for the chronic fatigue associated with the symptoms of Long-COVID; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist for improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. It has licensing agreements with Pegasus Advanced Research for use of mazindol for the treatment of ADHD. NLS Pharmaceutics AG was incorporated in 2015 and is headquartered in Zurich, Switzerland.
Compare NLSP to Peers and Sector
Metrics to compare | NLSP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNLSPPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.7x | −1.9x | −0.5x | |
PEG Ratio | −0.02 | 0.00 | 0.00 | |
Price/Book | −5.1x | −0.1x | 2.6x | |
Price / LTM Sales | - | 0.2x | 3.3x | |
Upside (Analyst Target) | - | 315.3% | 43.4% | |
Fair Value Upside | Unlock | −4.7% | 7.1% | Unlock |
Earnings
Latest Release
May 16, 2025
EPS / Forecast
-0.99 / --
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Stock Exchange Does NLS Pharmaceutics AG Trade On?
NLS Pharmaceutics AG is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for NLS Pharmaceutics AG?
The stock symbol for NLS Pharmaceutics AG is "NLSP."
What Is the NLS Pharmaceutics AG Market Cap?
As of today, NLS Pharmaceutics AG market cap is 6.76M.
What Is NLS Pharmaceutics AG's Earnings Per Share (TTM)?
The NLS Pharmaceutics AG EPS (TTM) is -2.63.
From a Technical Analysis Perspective, Is NLSP a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
How Many Times Has NLS Pharmaceutics AG Stock Split?
NLS Pharmaceutics AG has split 1 times.
How Many Employees Does NLS Pharmaceutics AG Have?
NLS Pharmaceutics AG has 0 employees.
What is the current trading status of NLS Pharmaceutics AG (NLSP)?
As of 10 Aug 2025, NLS Pharmaceutics AG (NLSP) is trading at a price of 2.14, with a previous close of 2.02. The stock has fluctuated within a day range of 1.99 to 2.18, while its 52-week range spans from 1.30 to 7.96.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.